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Abstract
Background: The influence of streptococcal infections in the pathogenesis of psoriasis is not yet
understood. In vitro data suggest that streptococcal factors influence T-cell function in psoriasis in
a HLA-dependent manner, but studies designed to measure the HLA-C/Streptococci interaction
are lacking. In the present study, we hypothesized that there is a statistical interaction between the
result of streptococcal throat cultures and the presence of the HLA-Cw*0602 allele in psoriasis
patients.
Methods: We performed a case control study using the "Stockholm Psoriasis Cohort" consisting
of patients consecutively recruited within 12 months of disease onset (Plaque psoriasis = 439,
Guttate psoriasis = 143), matched to healthy controls (n = 454) randomly chosen from the Swedish
Population Registry. All individuals underwent physical examination including throat swabs and
DNA isolation for HLA-Cw*0602 genotyping.
The prevalence of positive streptococcal throat swabs and HLA-Cw*0602 was compared between
patients and controls and expressed as odds ratios with 95% confidence intervals. Associations
were evaluated separately for guttate and plaque psoriasis by Fisher's exact test.
Results: Regardless of disease phenotype, the prevalence of positive streptococcal throat swabs
in HLA-Cw*0602 positive patients was twice the prevalence among HLA-Cw*0602 negative
patients (OR = 5.8 C.I. = 3.57–9.67, p < 0.001), while no difference was observed among Cw*0602
positive versus negative controls.
The corresponding odds ratios for the guttate and plaque psoriasis phenotypes were 3.5 (CI = 1.5–
8.7, p = 0.01) and 2.3 (CI = 1.0–5.1, p = 0.02) respectively.
Conclusion:  These findings suggest that among HLA-Cw*0602 positive psoriasis patients,
streptococci may contribute to the onset or exacerbation of the inflammatory process
independent of the disease phenotype. However, studies on the functional interaction between
HLA-C and streptococcal factors are needed.
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Background
Psoriasis is phenotypically and genetically heterogeneous
and associates with various environmental triggers. Gene-
environment interactions are relevant for complex dis-
eases [1,2]; for example, smoking influences seropositive
rheumatoid arthritis in an HLA-DR-dependent manner
[3]. In psoriasis, so far, only circumstantial evidence links
streptococcal infections to HLA-Cw*0602 status, mainly
in the guttate phenotype [4-8]. HLA genotypes are
reported to influence T-cell proliferation in response to
streptococcal antigens in vitro [9,10] and streptococci are
known to modulate immune responses through molecu-
lar mimicry [11]. In vitro studies show homology between
streptococcal M-proteins and human keratins, which may
influence T-cell responses [10]. However, assessment of
associations between streptococcal infection and HLA-
Cw6 at the population level is needed [12-18]. The
present work addresses this by investigating the preva-
lence of positive streptococcal throat swabs in guttate
(GP) and plaque psoriasis (PP) in relation to HLA-
Cw*0602 status.
Methods
Study subjects
Patients from the "Stockholm Psoriasis Cohort" (PP =
439, GP = 143) were consecutively recruited within 12
months of disease onset [15]. Psoriasis was diagnosed
according to established criteria [19]. Matched healthy
controls (n = 454) were randomly chosen from the Swed-
ish Population Registry. All individuals underwent physi-
cal examination including throat swab. To account for
seasonal variations, throat swabs from matched cases and
controls were obtained at the same time of the year. Blood
samples were obtained for DNA extraction. Written
informed consent was given by all individuals. The study
was approved by the Regional Committee of Ethics and
performed according to the Declaration of Helsinki Prin-
ciples.
HLA-Cw*0602 genotyping
Genotyping was performed by allele specific PCR amplifi-
cation of HLA-Cw*0602 as described [20].
Statistical Analyses
The prevalence of positive streptococcal throat swabs and
HLA-Cw*0602 was compared between patients and con-
trols and expressed as odds ratios with 95% confidence
intervals. Associations were evaluated separately for GP
and PP by Fisher's exact test. Analyses were performed
using the Statistical Analysis System package [21].
Results
Demographic and clinical characteristics
Age at onset ranged from 14–84 years, with a mean age of
32 for GP, 44 for PP and 40 for controls. The sex distribu-
tion was slightly skewed with a female predominance
(controls: 60%, GP: 58% and PP: 54%). Overall, 2/3 of
patients had mild psoriasis. The mean PASI-score was 5.6
for GP and 3.7 for PP. The delay time between the first
psoriasis lesion and clinical examination was 4.0 months
for GP and 7.5 months for PP.
Streptococcal throat status
All bacterial strains isolated from patients were β-hemo-
lytic Streptococcus pyogenes, group A (76%), C (8%) and G
(16%). In controls, no group A streptococci were isolated,
7 individuals had group G and one had group C. Positive
streptococcus isolation was 7.9 and 27.5 times more prev-
alent in GP patients compared to PP and controls respec-
tively (Table 1).
HLA-Cw*0602 associates strongly with GP
Regardless of disease phenotype, there were 240 HLA-
Cw*0602 positive and 342 negative patients and 49 HLA-
Cw*0602 positive and 405 negative controls (Table 1).
Table 1: HLA-Cw*0602 and streptococcal status
Positive Negative ORa
N % N % OR 95% CIb p
HLA-Cw*0602
Guttate (n = 143) 106 74 37 26 23.7 14.3–39.3 <0.001
Plaque (n = 439) 134 31 305 69 3.6 2.5–5.3 <0.001
Control (n = 454) 49 11 405 89
Streptococcus throat swab
Guttate (n = 143) 79 55 64 45 68.8 31–170 <0.001
Plaque (n = 439) 31 7 408 93 4.2 1.9–10.8 <0.001
Control (n = 454) 8 2 446 98
aOR = Odds Ratio (Patients compared to the healthy control)
bCI = confidence intervalBMC Dermatology 2009, 9:5 http://www.biomedcentral.com/1471-5945/9/5
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HLA-Cw*0602 was more frequent in GP (74%) compared
with PP (31%) and controls (11%), (Table 1).
Twofold higher prevalence of positive streptococcal throat 
swabs in HLA-Cw*0602 positive psoriasis patients
In absolute numbers, there were significantly more GP
patients with a positive streptococcal culture who carried
HLA-Cw*0602 (67/143), compared to PP (15/439).
However, in both groups, the prevalence of positive strep-
tococcal cultures increased approximately twofold among
Cw*0602 positive patients (GP: ×1.97; PP: ×2.2), while
no difference was observed among controls (Table 2).
Discussion
A link between streptococcal infections and several
autoimmune disorders has been observed, the clearest
being cardiac and renal damage due to cross-reactivity
with streptococcal antigens [22,23]. Interestingly, a recent
study showed that the global epidemiological variation in
psoriasis prevalence correlates closely with that of histori-
cal mortality from epidemics of invasive streptococcal
infections. The study suggested that the psoriasis genotype
could confer a degree of protection from mortality in such
epidemics [24]. In psoriasis, numerous studies suggest a
role for streptococcal factors in triggering disease, particu-
larly for GP [13,15,25,26]. It has been proposed that pso-
riasis may be due to autoimmunity resulting from cross-
reaction between streptococcal and skin epitopes, such as
streptococcal M protein and keratin [27], or cytokines
released by the superantigen stimulated T cells [28]. Also,
peptidoglycan (PG), the major constituent of the strepto-
coccal cell wall, has been suggested to acts as a T cell acti-
vator in psoriasis [29].
Since psoriasis has a strong genetic basis, associating to
HLA-Cw*0602 [30], and since this molecule has an
important immunological role an interaction between
HLA-Cw*0602 and streptococci has been suggested [31].
The present study hypothesized that in the initial stages of
disease, the prevalence of streptococcus positive cultures
is higher among HLA-Cw*0602 positive psoriasis
patients.
Consistent with previous reports, our results demonstrate
that HLA-Cw*0602 is more prevalent among young
patients and in GP [32,33]. Also, in accordance with other
reports, we observed that streptococcal throat infection
was more common in GP at disease onset [13,17]. This
could be partly explained by earlier medical attention for
GP, due to the acuteness of the disease, compared to PP.
In this study, the time between disease onset and strepto-
coccus swabs was variable. In most cases culture for strep-
tococcus was performed a few weeks after the onset of
psoriasis. Thus, the presence of streptococcus may in some
cases be unrelated to psoriasis. However, the fact that after
accounting for seasonal variations, positive cultures were
significantly more prevalent among patients than controls
indicates that these factors are likely related.
The main finding of the study is the twofold increased
prevalence of positive streptococcal throat swabs among
HLA-Cw*0602 positive patients compared to negative
patients, regardless of disease phenotype, suggesting that
the interaction between HLA-Cw*0602 and streptococci
modulate disease independent of clinical subtype. As
expected, the frequency of positive streptococcal cultures
among healthy controls was low (2%), indicating that car-
rying HLA-Cw*0602 does not increase the risk of strepto-
coccal throat infection.
Even though several groups studied HLA-Cw*0602 and
streptococcal infection independently [12-16], only one
Irish study investigated their interaction in 64 patients
with GP, 41 patients with PP and 20 controls [17]. They
concluded that HLA-Cw*0602 is not essential for strepto-
coccal-induced psoriasis. However, it is feasible that dif-
ferent genetic factors influence the expression of HLA-
Cw*0602 and the prevalence of streptococci throat infec-
tion among different population. Still, these factors may
contribute to onset of psoriasis.
Compared with other studies in Caucasians, the preva-
lence of HLA-Cw*0602 positive individuals in the Irish
study was surprisingly high among PP patients (73%) and
among controls (18%) [17]. However, it is conceivable
that the higher prevalence of HLA-Cw6 in the general
Table 2: Interaction between HLA-Cw*0602 and streptococcal status
-/+ +/+ ORa
N%N%O R 9 5 %  C I p
HLA-Cw*0602/Streptococci
Guttate (n = 143) 12 32 67 63 3.5 1.5–8.7 <0.01
Plaque (n = 439) 16 5 15 11 2.3 1.0–5.1 <0.02
Control (n = 454) 7 2 1 2 1.2 0.02–9.7 0.6
aOR = Odds Ratio (HLA-Cw*0602 positive individuals compared to HLA-Cw*0602 negative individuals)
bCI = confidence intervalBMC Dermatology 2009, 9:5 http://www.biomedcentral.com/1471-5945/9/5
Page 4 of 5
(page number not for citation purposes)
population reflects a higher prevalence of psoriasis in that
population.
Neither HLA-Cw*0602, nor streptococcal infections per se
seem necessary for disease development, because there are
psoriasis patients that do not carry HLA-Cw*0602 and
develop disease without signs of streptococcal infection. It
is possible that other HLA-C alleles may substitute for
Cw*0602 when interacting with streptococci, and also,
other triggering factors besides streptococci may contrib-
ute to disease through HLA-Cw*0602.
Conclusion
There is growing awareness that the clinical subtypes of
psoriasis may have different genetic backgrounds, which
has implications for study design when trying to measure
gene/environment associations [34]. Yet, we observed
that the HLA-Cw*0602/streptococci interaction was inde-
pendent of disease phenotype, even though the absolute
numbers were small among plaque patients. It is still
unclear how this combination of factors influences the
expression of clinical manifestations of psoriasis, there-
fore functional assessment of HLA-Cw*0602/streptococci
interaction is required.
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